Clinical Trial Detail

NCT ID NCT03066648
Title Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Decitabine + Spartalizumab

Decitabine + Sabatolimab + Spartalizumab

Decitabine + Sabatolimab

Age Groups: senior adult

No variant requirements are available.